Most Read Articles
Pank Jit Sin, 30 Nov 2018
The use of pertuzumab in the adjuvant setting significantly increases the rate of invasive-disease-free survival (IDFS) of persons with HER2+ early breast cancer (eBC). 

Podcast: CGP in NSCLC with Dr Alexander Drilon

07 Jul 2017
Podcast: CGP in NSCLC with Dr Alexander Drilon
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 30 Nov 2018
The use of pertuzumab in the adjuvant setting significantly increases the rate of invasive-disease-free survival (IDFS) of persons with HER2+ early breast cancer (eBC).